Objective: To report daytime sleepiness data from the phase 2 clinical trial of tavapadon in participants with early early-stage Parkinson’s disease (PD) utilizing the Epworth Sleepiness Scale (ESS).
Objective: To report daytime sleepiness data from the phase 2 clinical trial of tavapadon in participants with early early-stage Parkinson’s disease (PD) utilizing the Epworth Sleepiness Scale (ESS).
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.